ESM Technologies, the manufacturer of leading eggshell membrane ingredient, NEM® has additional research published to explain how NEM brand eggshell membrane supports healthy joints.
NEM brand eggshell membrane has been shown previously to reduce pro-inflammatory cytokines in vitro in mitogen-challenged, healthy human immune cells—and now this mechanism of action has been extended to in vivo studies as well. The results from these studies, recently published in Modern Research in Inflammation, showed substantial reductions of a variety of pro-inflammatory cytokines while, importantly, having little effect on the anti-inflammatory cytokines evaluated. The initial studies in healthy rats demonstrated large reductions (up to 88 percent) in cytokines that occur later in the inflammatory cascade (e.g. MCP-1, MIP-1?, RANTES, VEGF). Whereas a follow-up study in inflammatory-challenged rats demonstrated significant reductions (40 to 44 percent) in IL-1?, a key primary mediator of inflammation.
Kevin J. Ruff, Ph.D., MBA, CCRP, director of scientific and regulatory affairs at ESM Technologies, stated, “We were pleased to find evidence that NEM helps to maintain a normal inflammatory response in healthy animals. And the novel nature of this finding formed the basis for a patent (U.S. 8,580,315) that was recently granted for this same indication.” Taken together, these studies establish that oral supplementation with NEM can influence quite a number of cytokines associated with the progression of cartilage destruction within joints, providing a plausible basis for the mechanism of action of NEM in vivo; and this serves as an important step in explaining its observed clinical efficacy seen in multiple human studies.
These additional published studies show further substantiation for NEM supporting a healthy inflammatory response. The paper has published online Modern Research in Inflammation.